Advertisement
Screener

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Net Income (Loss) Attributable to Noncontrolling Interest

2.7 / 5 stars · 59/108 Roast Me

ARROWHEAD PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Noncontrolling Interest

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Net Income (Loss) Attributable to Noncontrolling Interest of $15.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Income Statement › Net Income

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-04

  • ARROWHEAD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was $15.36M.
  • ARROWHEAD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$4.84M.
  • ARROWHEAD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$2.57M.
  • ARROWHEAD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was $39.87M.
  • ARROWHEAD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2025 was $31.75M.
  • ARROWHEAD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$10.20M.
  • ARROWHEAD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2023 was -$4.00M.
  • ARROWHEAD PHARMACEUTICALS, INC. net income (loss) attributable to noncontrolling interest for fiscal 2022 was -$431.00K.
Period endNet Income (Loss) Attributable to Noncontrolling Interest 3 monthNet Income (Loss) Attributable to Noncontrolling Interest 6 monthNet Income (Loss) Attributable to Noncontrolling Interest 9 monthNet Income (Loss) Attributable to Noncontrolling Interest 12 monthNet Income (Loss) Attributable to Noncontrolling Interest 98 monthNet Income (Loss) Attributable to Noncontrolling Interest 101 monthNet Income (Loss) Attributable to Noncontrolling Interest 104 monthNet Income (Loss) Attributable to Noncontrolling Interest 107 monthNet Income (Loss) Attributable to Noncontrolling Interest 110 monthNet Income (Loss) Attributable to Noncontrolling Interest 113 monthNet Income (Loss) Attributable to Noncontrolling Interest 116 monthNet Income (Loss) Attributable to Noncontrolling Interest 119 monthNet Income (Loss) Attributable to Noncontrolling Interest 122 monthNet Income (Loss) Attributable to Noncontrolling Interest 125 monthNet Income (Loss) Attributable to Noncontrolling Interest 128 monthNet Income (Loss) Attributable to Noncontrolling Interest 131 month
2026-06-30$15.36M
10-Q · filed 2026-08-04
$10.52M
derived: sum of 2 quarters · filed 2026-08-04
$7.96M
10-Q · filed 2026-08-04
$47.83M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31-$4.84M
10-Q · filed 2026-05-07
-$7.41M
10-Q · filed 2026-05-07
$32.46M
derived: sum of 3 quarters · filed 2026-05-07
$29.05M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31-$2.57M
10-Q · filed 2026-02-05
$37.30M
derived: sum of 2 quarters · filed 2026-02-05
$33.89M
derived: sum of 3 quarters · filed 2026-08-04
$31.31M
derived: sum of 4 quarters · filed 2026-08-04
2025-09-30$39.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25
$36.46M
derived: sum of 2 quarters · filed 2026-08-04
$33.88M
derived: sum of 3 quarters · filed 2026-08-04
$31.75M
10-K · filed 2025-11-25
2025-06-30-$3.41M
10-Q · filed 2026-08-04
-$5.99M
derived: sum of 2 quarters · filed 2026-08-04
-$8.13M
10-Q · filed 2026-08-04
-$10.93M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31-$2.58M
10-Q · filed 2026-05-07
-$4.71M
10-Q · filed 2026-05-07
-$7.52M
derived: sum of 3 quarters · filed 2026-05-07
-$10.71M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$2.13M
10-Q · filed 2026-02-05
-$4.94M
derived: sum of 2 quarters · filed 2026-02-05
-$8.13M
derived: sum of 3 quarters · filed 2026-02-05
-$9.82M
derived: sum of 4 quarters · filed 2026-02-05
2024-09-30-$2.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25
-$5.99M
derived: sum of 2 quarters · filed 2025-11-25
-$7.69M
derived: sum of 3 quarters · filed 2025-11-25
-$10.20M
10-K · filed 2025-11-25
2024-06-30-$3.18M
10-Q · filed 2025-08-07
-$4.88M
derived: sum of 2 quarters · filed 2025-08-07
-$7.39M
10-Q · filed 2025-08-07
-$8.73M
derived: sum of 4 quarters · filed 2025-11-25
2024-03-31-$1.70M
10-Q · filed 2025-05-12
-$4.21M
10-Q · filed 2025-05-12
-$5.54M
derived: sum of 3 quarters · filed 2025-11-25
-$6.72M
derived: sum of 4 quarters · filed 2025-11-25
2023-12-31-$2.51M
10-Q · filed 2025-02-10
-$3.85M
derived: sum of 2 quarters · filed 2025-11-25
-$5.03M
derived: sum of 3 quarters · filed 2025-11-25
-$6.03M
derived: sum of 4 quarters · filed 2025-11-25
2023-09-30-$1.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25
-$2.52M
derived: sum of 2 quarters · filed 2025-11-25
-$3.51M
derived: sum of 3 quarters · filed 2025-11-25
-$4.00M
10-K · filed 2025-11-25
2023-06-30-$1.18M
10-Q · filed 2024-08-08
-$2.18M
derived: sum of 2 quarters · filed 2024-08-08
-$2.66M
10-Q · filed 2024-08-08
-$3.10M
derived: sum of 4 quarters · filed 2024-11-26
2023-03-31-$999.00K
10-Q · filed 2024-05-09
-$1.49M
10-Q · filed 2024-05-09
-$1.92M
derived: sum of 3 quarters · filed 2024-11-26
-$1.92M
derived: sum of 4 quarters · filed 2024-11-26
2022-12-31-$486.00K
10-Q · filed 2024-02-06
-$917.00K
derived: sum of 2 quarters · filed 2024-11-26
-$917.00K
derived: sum of 3 quarters · filed 2024-11-26
-$917.00K
derived: sum of 4 quarters · filed 2024-11-26
2022-09-30-$431.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26
-$431.00K
derived: sum of 2 quarters · filed 2024-11-26
-$431.00K
derived: sum of 3 quarters · filed 2024-11-26
-$431.00K
10-K · filed 2024-11-26
2022-06-30$0.00
10-Q · filed 2023-08-07
$0.00
derived: sum of 2 quarters · filed 2023-08-07
$0.00
10-Q · filed 2023-08-07
2022-03-31$0.00
10-Q · filed 2023-05-02
$0.00
10-Q · filed 2023-05-02
2021-12-31$0.00
10-Q · filed 2023-02-06
2021-09-30$0.00
10-K · filed 2023-11-29
2020-09-30$0.00
10-K · filed 2022-11-28
2014-09-30-$90.00
derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14
$2.38K
derived: sum of 2 quarters · filed 2016-12-14
-$37.80K
derived: sum of 3 quarters · filed 2016-12-14
-$95.22K
10-K · filed 2016-12-14
2014-06-30$2.47K
10-Q · filed 2015-08-04
-$37.71K
derived: sum of 2 quarters · filed 2015-08-04
-$95.13K
10-Q · filed 2015-08-04
-$208.01K
derived: sum of 4 quarters · filed 2015-12-14
2014-03-31-$40.18K
10-Q · filed 2015-05-11
-$97.60K
10-Q · filed 2015-05-11
-$210.47K
derived: sum of 3 quarters · filed 2015-12-14
-$309.09K
derived: sum of 4 quarters · filed 2015-12-14
-$19.48M
10-Q · filed 2014-05-06
2013-12-31-$57.42K
10-Q · filed 2015-02-09
-$170.30K
derived: sum of 2 quarters · filed 2015-12-14
-$268.91K
derived: sum of 3 quarters · filed 2015-12-14
-$451.00K
derived: sum of 4 quarters · filed 2015-12-14
-$19.44M
10-Q · filed 2014-02-04
2013-09-30-$112.88K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-14
-$211.49K
derived: sum of 2 quarters · filed 2015-12-14
-$393.58K
derived: sum of 3 quarters · filed 2015-12-14
-$560.14K
10-K · filed 2015-12-14
-$19.38M
10-K · filed 2013-12-18
2013-06-30-$98.62K
10-Q · filed 2014-08-12
-$280.70K
derived: sum of 2 quarters · filed 2014-08-12
-$447.27K
10-Q · filed 2014-08-12
-$734.34K
derived: sum of 4 quarters · filed 2014-11-25
-$19.27M
10-Q · filed 2013-08-07
2013-03-31-$182.08K
10-Q · filed 2014-05-06
-$348.65K
10-Q · filed 2014-05-06
-$635.72K
derived: sum of 3 quarters · filed 2014-11-25
-$883.27K
derived: sum of 4 quarters · filed 2014-11-25
-$19.17M
10-Q · filed 2013-05-09
2012-12-31-$166.57K
10-Q · filed 2014-02-04
-$453.64K
derived: sum of 2 quarters · filed 2014-11-25
-$701.19K
derived: sum of 3 quarters · filed 2014-11-25
-$950.07K
derived: sum of 4 quarters · filed 2014-11-25
-$18.99M
10-Q · filed 2013-02-13
2012-09-30-$287.07K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-25
-$534.62K
derived: sum of 2 quarters · filed 2014-11-25
-$783.50K
derived: sum of 3 quarters · filed 2014-11-25
-$984.79K
10-K · filed 2014-11-25
-$18.82M
10-K · filed 2012-12-28
2012-06-30-$247.55K
10-Q · filed 2013-08-07
-$496.43K
derived: sum of 2 quarters · filed 2013-08-07
-$697.73K
10-Q · filed 2013-08-07
-$868.14K
derived: sum of 4 quarters · filed 2013-08-07
-$18.53M
10-Q · filed 2012-08-13
2012-03-31-$248.88K
10-Q · filed 2013-05-09
-$450.18K
10-Q · filed 2013-05-09
-$620.59K
derived: sum of 3 quarters · filed 2013-05-09
-$814.09K
derived: sum of 4 quarters · filed 2013-05-09
-$18.28M
10-Q · filed 2012-05-08
2011-12-31-$201.29K
10-Q · filed 2013-02-13
-$371.71K
derived: sum of 2 quarters · filed 2013-02-13
-$565.21K
derived: sum of 3 quarters · filed 2013-02-13
-$771.06K
derived: sum of 4 quarters · filed 2013-02-13
-$18.04M
10-Q · filed 2012-02-09
2011-09-30-$170.41K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-12-28
-$363.91K
derived: sum of 2 quarters · filed 2012-12-28
-$569.77K
derived: sum of 3 quarters · filed 2012-12-28
-$363.51K
10-K · filed 2012-12-28
-$17.83M
10-Q · filed 2012-08-13
2011-06-30-$193.50K
10-Q · filed 2012-08-13
-$399.35K
derived: sum of 2 quarters · filed 2012-08-13
-$193.10K
10-Q · filed 2012-08-13
-$503.21K
derived: sum of 4 quarters · filed 2012-08-13
-$17.66M
10-Q · filed 2011-08-08
2011-03-31-$205.85K
10-Q · filed 2012-05-08
$398.00
10-Q · filed 2012-05-08
-$309.71K
derived: sum of 3 quarters · filed 2012-05-08
-$622.45K
derived: sum of 4 quarters · filed 2012-05-08
2010-12-31$206.25K
10-Q · filed 2012-02-09
-$103.86K
derived: sum of 2 quarters · filed 2012-02-09
-$416.60K
derived: sum of 3 quarters · filed 2012-02-09
2010-09-30-$310.11K
derived: 10-K 12 month − 10-Q 9 month · filed 2011-12-20
-$622.85K
derived: sum of 2 quarters · filed 2011-12-20
-$1.18M
10-K · filed 2011-12-20
2010-06-30-$312.74K
10-Q · filed 2011-08-08
-$872.88K
10-Q · filed 2011-08-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Alkermes plc. (ALKS)$6.844B132.74